Rebalix
Logo AmundiAmundi · sheet of 5 September 2026
ETF sheet · official issuer and register data

Amundi Label ISR Actions Europe UCITS ETF Acc

ISRA · FR001400SDI8 · class Acc · EUR · domicile France
Equity · Europe · Sustainable / ESGactiveSFDR art. 8
Comparison benchmark: MSCI Europe Net Return EUR Index
TER
0.20%+ trans. 0.17%
Fund size
149 m EUR
Tracking difference
not computable
🇮🇹 tax rate
white list not published
Replication
Physicalactive management
Income
Accumulating
Launch 27 Nov 2024 · costs from the KID as of 2 Sept 2026 · 183 securities held · 4 venues (ESMA register)

The fund’s objective — in the issuer’s words

From the Key Information Document (KID) · unofficial translation, the original prevails · 4 Aug 2026
The Fund is an actively managed UCITS. By subscribing to AMUNDI Label ISR Actions Europe UCITS ETF - Acc, you invest in an actively managed UCITS whose objective is to obtain an exposure to large and mid market capitalisations of European developed markets while improving environmental, social and governance ("ESG") criteria in the process of selecting and analysing the portfolio's securities relative to the MSCI Europe Index index (the "Benchmark Indicator"). The Benchmark Indicator is the MSCI Europe index index, denominated in euros, net dividends…

Performance since series start (in euro) — base 100

27 Nov 20243 Sept 2026 · dividends reinvested where declared by the issuer
2025202613293130
High 132 (7 Aug 2026) · low 93 (9 Apr 2025) · last 130. Past performance is not indicative of future results.

Returns in euro

1 year+21.1%
3 yearsseries too young
5 yearsseries too young
10 yearsseries too young
Since series start+29.8%

Risk · 1 / 3 / 5 years

Volatility (ann.)12.97%12.97%
Max drawdown−10.63%−10.63%
Sharpe1.301.30
Sortino2.002.00
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · ISRA · FR001400SDI81
RebalixISRA · FR001400SDI8 · sheet of 5 September 2026

Tracking difference — year by year

Fund minus index, complete calendar years · declared by the issuer
YearFundIndexTD
2025+14.77%+19.39%−4.61%

Holdings

Portfolio as declared by the issuer · 1 Sept 2026 · 183 securities · top-10 weight = 24.7%
Top holdingsWeight
ASML HOLDING NV5.2%
HSBC HOLDINGS PLC3.0%
NOVARTIS AG-REG2.8%
SIEMENS AG-REG2.2%
BANCO SANTANDER SA MADRID2.2%
ALLIANZ SE-REG2.1%
ASTRAZENECA GBP1.9%
SAP SE / XETRA1.8%
UNILEVER PLC LONDON1.7%
ABB LTD-REG1.7%
Countries (% of fund)
United Kingdom23.1%France14.3%Switzerland14.0%Germany13.5%Netherlands8.7%
Sectors (% of fund)
Financials26.5%Industrials18.8%Health Care13.8%Information Technology9.5%Consumer Staples9.1%

Listing venues

ESMA register (FIRDS) and official exchange lists
AE59 · Börse Hannover, Börse Stuttgart, Tradegate Exchange
ISRA · Euronext Paris
+ 10 unmapped venues (MTF, RFQ, professional)

Official documents

Clickable links in the PDF
KID · www.amundietf.it/pdfDocuments/kid-priips/FR001400SDI8/FRA/FRA
Factsheet · www.amundietf.it/pdfDocuments/monthly-factsheet/FR001400SDI8/FRA/FRA/I
Prospectus · www.amundietf.it/pdfDocuments/prospectus/FR001400SDI8/FRA/FRA
The live sheet, always up to date
rebalix.com/en/etf/FR001400SDI8
Series, distributions, holdings and documents refresh daily.
Sheet produced on 5 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.

Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.

Rebalix · ISRA · FR001400SDI82